Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
Abstract Objectives Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tum...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-06-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13104-019-4368-z |
| _version_ | 1819061549878214656 |
|---|---|
| author | Javier Sánchez Ramírez Mónica Bequet-Romero Yanelys Morera Díaz Francisco Hernández-Bernal Marta Ayala Avila |
| author_facet | Javier Sánchez Ramírez Mónica Bequet-Romero Yanelys Morera Díaz Francisco Hernández-Bernal Marta Ayala Avila |
| author_sort | Javier Sánchez Ramírez |
| collection | DOAJ |
| description | Abstract Objectives Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tumors. This specific active immunotherapy is able to reduce platelet VEGF levels; however it is unknown whether this effect leads to a decrease in VEGF below the levels that can be observed in healthy individuals. The objective of the present study is to investigate platelet VEGF levels in cancer patients vaccinated with CIGB-247, and then compare these values with those obtained in healthy individuals. To achieve this, platelet VEGF levels of 62 cancer patients and 93 healthy individuals were compared. Cancer patients were those individuals recruited in CENTAURO and CENTAURO-2 clinical trials. Results Before vaccination, platelets of cancer patients carried more VEGF than the levels seen in platelet of healthy individuals. However, after vaccination, cancer patients had platelet VEGF values within the range established by healthy individuals, indicating that the antibody response elicited by CIGB-247 is not able to induce a complete suppression of VEGF. Vaccination with CIGB-247 helps to normalize VEGF levels within platelets. |
| first_indexed | 2024-12-21T14:44:40Z |
| format | Article |
| id | doaj.art-e61ac35805b345c282c265264e037430 |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-12-21T14:44:40Z |
| publishDate | 2019-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-e61ac35805b345c282c265264e0374302022-12-21T19:00:04ZengBMCBMC Research Notes1756-05002019-06-011211510.1186/s13104-019-4368-zDoes VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?Javier Sánchez Ramírez0Mónica Bequet-Romero1Yanelys Morera Díaz2Francisco Hernández-Bernal3Marta Ayala Avila4Department of Pharmaceuticals, Center for Genetic Engineering and BiotechnologyDepartment of Pharmaceuticals, Center for Genetic Engineering and BiotechnologyDepartment of Pharmaceuticals, Center for Genetic Engineering and BiotechnologyDepartment of Clinical Research, Center for Genetic Engineering and BiotechnologyDepartment of Pharmaceuticals, Center for Genetic Engineering and BiotechnologyAbstract Objectives Vascular endothelial growth factor (VEGF) is involved in physiological angiogenesis, but also is considered one of the key factors that promotes tumor angiogenesis. CIGB-247 is a VEGF-based vaccine that has been evaluated in phase I clinical trial patients with advanced solid tumors. This specific active immunotherapy is able to reduce platelet VEGF levels; however it is unknown whether this effect leads to a decrease in VEGF below the levels that can be observed in healthy individuals. The objective of the present study is to investigate platelet VEGF levels in cancer patients vaccinated with CIGB-247, and then compare these values with those obtained in healthy individuals. To achieve this, platelet VEGF levels of 62 cancer patients and 93 healthy individuals were compared. Cancer patients were those individuals recruited in CENTAURO and CENTAURO-2 clinical trials. Results Before vaccination, platelets of cancer patients carried more VEGF than the levels seen in platelet of healthy individuals. However, after vaccination, cancer patients had platelet VEGF values within the range established by healthy individuals, indicating that the antibody response elicited by CIGB-247 is not able to induce a complete suppression of VEGF. Vaccination with CIGB-247 helps to normalize VEGF levels within platelets.http://link.springer.com/article/10.1186/s13104-019-4368-zSpecific active immunotherapyVEGF vaccineCIGB-247PlateletsPhase I clinical trial |
| spellingShingle | Javier Sánchez Ramírez Mónica Bequet-Romero Yanelys Morera Díaz Francisco Hernández-Bernal Marta Ayala Avila Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? BMC Research Notes Specific active immunotherapy VEGF vaccine CIGB-247 Platelets Phase I clinical trial |
| title | Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? |
| title_full | Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? |
| title_fullStr | Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? |
| title_full_unstemmed | Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? |
| title_short | Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels? |
| title_sort | does vegf targeted active immunotherapy induce complete abrogation of platelet vegf levels |
| topic | Specific active immunotherapy VEGF vaccine CIGB-247 Platelets Phase I clinical trial |
| url | http://link.springer.com/article/10.1186/s13104-019-4368-z |
| work_keys_str_mv | AT javiersanchezramirez doesvegftargetedactiveimmunotherapyinducecompleteabrogationofplateletvegflevels AT monicabequetromero doesvegftargetedactiveimmunotherapyinducecompleteabrogationofplateletvegflevels AT yanelysmoreradiaz doesvegftargetedactiveimmunotherapyinducecompleteabrogationofplateletvegflevels AT franciscohernandezbernal doesvegftargetedactiveimmunotherapyinducecompleteabrogationofplateletvegflevels AT martaayalaavila doesvegftargetedactiveimmunotherapyinducecompleteabrogationofplateletvegflevels |